Chemical engineering

NewHydrogen CEO Steve Hill Discusses Advancements in Sustainable Hydrogen Catalysts with Hampton University Energy Expert

Retrieved on: 
Tuesday, November 21, 2023

SANTA CLARITA, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- NewHydrogen, Inc. (OTCMKTS:NEWH), the developer of a breakthrough technology that uses clean energy and water to produce the world’s cheapest green hydrogen, today announced that in a recent podcast the Company’s CEO Steve Hill spoke with Hampton University's Chair and Professor of Chemical Engineering, Dr. Mohamed Sanad Noufal regarding catalyst research, sustainable hydrogen production, and the path to affordable, clean energy solutions.

Key Points: 
  • Dr. Noufal emphasized the pivotal role of catalysts in addressing global energy challenges, emphasizing the need for a fundamental understanding of their processes.
  • These catalysts promise to enhance the efficiency of hydrogen and oxygen electrochemical reactions, a vital component of sustainable energy production.
  • His commitment to developing sustainable catalysts that combine efficiency with reproducibility is poised to revolutionize hydrogen production and fuel cell conversion.
  • Watch the full discussion on the NewHydrogen Podcast featuring Dr. Noufal at https://newhydrogen.com/single-video.php?id=at3pL6ooXCo
    For more information about NewHydrogen, please visit https://newhydrogen.com/ .

Scribe Therapeutics Appoints Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, and Dr. Maria Mirotsou as Vice President of Discovery Biology

Retrieved on: 
Wednesday, December 20, 2023

Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced the appointments of Aarif Khakoo, M.D., M.B.A., as Chief Scientific Officer and Head of Research and Development (R&D), and Maria Mirotsou, M.Sc., Ph.D., as Vice President of Discovery Biology.

Key Points: 
  • Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced the appointments of Aarif Khakoo, M.D., M.B.A., as Chief Scientific Officer and Head of Research and Development (R&D), and Maria Mirotsou, M.Sc., Ph.D., as Vice President of Discovery Biology.
  • “We are thrilled to welcome Aarif and Maria to our world-class team of CRISPR technologists, leading scientists, and proven company builders,” said Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe.
  • “Aarif brings a wealth of clinical and R&D experience treating a broad range of diseases, including cardiometabolic disorders.
  • He will help lead and manage Scribe’s research and innovation in areas including discovery, technology, molecular engineering, biology, and more,” continued Dr. Oakes.

Announcement of the List of 2023 Golden Flag Awards Unveils Five Major Trends in Communication Strategies for the Chinese Market

Retrieved on: 
Wednesday, December 20, 2023

These award-winning cases provide insights into the current communication strategies and trends in the Chinese market, many of which have gained significant traction over the past year.

Key Points: 
  • These award-winning cases provide insights into the current communication strategies and trends in the Chinese market, many of which have gained significant traction over the past year.
  • Data from submissions for this year's Golden Flag Award reveals five major trends in brand communication strategies in the Chinese market:
    1.
  • The majority of exemplary cases focus on corporate social responsibility, ESG communication, environmental protection, and public welfare communication.
  • In this year's brand communication cases in the Chinese market, digital communication methods have been widely embraced.

Dennis Willig Appointed CITGO Vice President of Refining; Ryan Vining Appointed Vice President and General Manager Corpus Christi Refinery

Retrieved on: 
Tuesday, December 19, 2023

Willig most recently served as Vice President and General Manager of the Corpus Christi Refinery, and prior to that was the Vice President and General Manager of the Lemont Refinery where he spent the majority of his 28-year career with CITGO.

Key Points: 
  • Willig most recently served as Vice President and General Manager of the Corpus Christi Refinery, and prior to that was the Vice President and General Manager of the Lemont Refinery where he spent the majority of his 28-year career with CITGO.
  • Replacing Willig as the new Vice President and General Manager Corpus Christi Refinery is Ryan Vining, who spent the last 24 years at the CITGO Lake Charles Refinery, most recently as General Manager Operations, Maintenance and Reliability.
  • "And adding Ryan Vining as Vice President and General Manager Corpus Christi Refinery further strengthens our leadership team."
  • Willig joined the CITGO Lemont Refinery in 1995 and advanced all the way to Vice President and General Manager Lemont Refinery before assuming the Vice President and General Manager position at the Corpus Christi Refinery in 2022.

SI Group Appoints Frank Yang as VP & Managing Director, Asia Pacific

Retrieved on: 
Tuesday, December 19, 2023

THE WOODLANDS, Texas, Dec. 19, 2023 /PRNewswire/ -- SI Group, a leading global developer and manufacturer of performance additives, process solutions, pharmaceuticals, and chemical intermediates, announced today it has appointed Frank Yang as VP & Managing Director, Asia Pacific, effective January 1, 2024. 

Key Points: 
  • THE WOODLANDS, Texas, Dec. 19, 2023 /PRNewswire/ -- SI Group, a leading global developer and manufacturer of performance additives, process solutions, pharmaceuticals, and chemical intermediates, announced today it has appointed Frank Yang as VP & Managing Director, Asia Pacific, effective January 1, 2024.
  • As the VP & Managing Director, Asia Pacific, Frank will lead SI Group's Asia Pacific management team.
  • As the VP & Managing Director, Asia Pacific, Frank will lead SI Group's Asia Pacific management team to optimize the business and deliver results in the region.
  • "With Frank as VP & Managing Director, Asia Pacific, we look forward to delivering more value to our customers and shareholders in the region now and in the future."

SI Group Appoints Frank Yang as VP & Managing Director, Asia Pacific

Retrieved on: 
Tuesday, December 19, 2023

THE WOODLANDS, Texas, Dec. 19, 2023 /PRNewswire/ -- SI Group, a leading global developer and manufacturer of performance additives, process solutions, pharmaceuticals, and chemical intermediates, announced today it has appointed Frank Yang as VP & Managing Director, Asia Pacific, effective January 1, 2024. 

Key Points: 
  • THE WOODLANDS, Texas, Dec. 19, 2023 /PRNewswire/ -- SI Group, a leading global developer and manufacturer of performance additives, process solutions, pharmaceuticals, and chemical intermediates, announced today it has appointed Frank Yang as VP & Managing Director, Asia Pacific, effective January 1, 2024.
  • As the VP & Managing Director, Asia Pacific, Frank will lead SI Group's Asia Pacific management team to optimize the business and deliver results in the region.
  • "With Frank as VP & Managing Director, Asia Pacific, we look forward to delivering more value to our customers and shareholders in the region now and in the future."
  • "SI Group has a strong brand and market presence in the region with opportunity for growth and an ambitious vision statement, making it an exciting organization to join," said Frank Yang.

Stradefy Biosciences Appoints Jeffrey M. Goldberg as Executive Chair

Retrieved on: 
Tuesday, December 19, 2023

NEW HAVEN, Conn., Dec. 19, 2023 /PRNewswire-PRWeb/ -- Stradefy Biosciences, a New Haven-based drug discovery and development company based on Yale University research, today announced the appointment of Jeffrey M. Goldberg as Executive Chair, effective immediately. Mr. Goldberg is an accomplished biotech executive with over 25 years of experience leading teams from preclinical discovery through commercialization. He previously served as President and Chief Executive Officer of both Immunitas Therapeutics and Aeglea Biotherapeutics, now Spyre Therapeutics.

Key Points: 
  • NEW HAVEN, Conn., Dec. 19, 2023 /PRNewswire-PRWeb/ -- Stradefy Biosciences , a New Haven-based drug discovery and development company based on Yale University research, today announced the appointment of Jeffrey M. Goldberg as Executive Chair, effective immediately.
  • Mr. Goldberg is an accomplished biotech executive with over 25 years of experience leading teams from preclinical discovery through commercialization.
  • He previously served as President and Chief Executive Officer of both Immunitas Therapeutics and Aeglea Biotherapeutics, now Spyre Therapeutics .
  • "I'm incredibly excited to be joining Stradefy and helping to facilitate the development of new technologies for patients battling devastating diseases," said Mr. Goldberg.

Lumen names industry AI expert as Chief Product Officer

Retrieved on: 
Monday, December 18, 2023

DENVER, Dec. 18, 2023 /PRNewswire/ -- Lumen Technologies (NYSE: LUMN) has named Dr. Satish Lakshmanan as its new Chief Product Officer. Dr. Lakshmanan will lead Lumen's corporate strategy and product portfolio, continuing to innovate network and advanced services to help customers thrive in today's digital economy. He will report to Lumen CEO Kate Johnson.

Key Points: 
  • DENVER, Dec. 18, 2023 /PRNewswire/ -- Lumen Technologies (NYSE: LUMN) has named Dr. Satish Lakshmanan as its new Chief Product Officer.
  • Dr. Lakshmanan will lead Lumen's corporate strategy and product portfolio, continuing to innovate network and advanced services to help customers thrive in today's digital economy.
  • Satish has a wealth of experience in building and scaling world-class products and services, leveraging Gen AI to accelerate digital transformations.
  • His experience, knowledge, and leadership style are a perfect match for Lumen as we disrupt the telecom industry by delighting customers with effortless digital experiences."

Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors

Retrieved on: 
Wednesday, November 15, 2023

Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space.

Key Points: 
  • Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space.
  • Dr Martin was instrumental in co-founding ADC Therapeutics (NYSE: ADCT) in Jan 2012 and served as its CEO since inception until May 2022.
  • Alongside his role as Chairman of Myricx, he is also Chairman of the Board of Tokamak Energy Ltd, and Tagworks Pharmaceuticals BV, and a Director on the Board of Osivax SAS.
  • Dr Robin Carr, Myricx CEO and Board Director, said, “We are thrilled that Chris has joined our Board and taken on the role of Chairman.

Michael Lynch, Veteran JPMorgan and Goldman Sachs Banker, Joins Foros as a Managing Director

Retrieved on: 
Tuesday, December 12, 2023

Foros announced today that Michael Lynch has joined the firm as a Managing Director.

Key Points: 
  • Foros announced today that Michael Lynch has joined the firm as a Managing Director.
  • Over the course of his career, Michael has built and run businesses for JPMorgan Chase & Co. and Goldman, Sachs & Co.
  • Prior to joining Foros, Michael was a Vice Chairman, Investment Banking at JP Morgan for 13 years, advising companies across sectors on critical strategic and capital markets issues.
  • I have tremendous respect for how he has built Foros, and I am delighted that we have this opportunity to work together again.”